cmAngio® vs Tempus ECG-Low EF
AI Verdict
Choose cmAngio® if…
Choose cmAngio® if your facility aims to leverage existing mammography screenings to provide an additional, non-invasive cardiovascular risk assessment for women. This tool is ideal for integrating early detection of Breast Arterial Calcifications (BAC) into routine breast imaging workflows, offering insights into potential cardiovascular health concerns without additional radiation or procedures. It is particularly suited for radiology and OB/GYN practices looking to enhance proactive patient care by identifying cardiovascular risk factors from standard mammograms.
View cmAngio® →Choose Tempus ECG-Low EF if…
Choose Tempus ECG-Low EF if your clinical setting requires an AI-powered solution to quickly screen patients aged 40 and older for signs associated with low left ventricular ejection fraction (LVEF) using standard 12-lead ECG recordings. This tool is best suited for cardiology, emergency medicine, and internal medicine departments seeking to identify patients at risk of heart failure for further evaluation, streamlining the diagnostic pathway for a critical cardiac condition.
View Tempus ECG-Low EF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cmAngio® | Tempus ECG-Low EF |
|---|---|---|
| Pricing | Paid, out-of-pocket | Unknown |
| Deployment | Cloud-based, integrates with any DICOM-compliant viewer | Integrates with current ECG platforms and electronic health records (EHRs). |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
cmAngio®Tool A (cmAngiou00ae) offers a more interactive and visually informative user experience, providing a scorecard with BAC visualization directly on mammogram images and an adjustable operating point to meet clinical goals. Its quick installation and compatibility with any DICOM-compliant viewer also suggest a smoother integration into existing radiology workflows.
Clinical Value
cmAngio®Both tools offer significant clinical value by identifying early cardiovascular risk. However, Tool A (cmAngiou00ae) uniquely leverages existing mammography data to provide a 'two-for-one exam' for both breast cancer and cardiovascular risk assessment without additional radiation or procedures, maximizing the utility of a routine screening. This ability to extract new, vital information from an already performed exam gives it a slight edge.
Pricing & Value
Tempus ECG-Low EFTool B (Tempus ECG-Low EF) demonstrates a clearer value proposition with confirmed Medicare reimbursement, effective January 1, 2025, at a rate of $128.90 per assessment. In contrast, Tool A (cmAngiou00ae) lacks transparent public pricing, only mentioning 'limited-time offers for no-cost implementation and service', making its long-term value harder to assess.
Enterprise Readiness
Tempus ECG-Low EFBoth tools are FDA-cleared and HIPAA-compliant, indicating a strong foundation for enterprise deployment. However, Tool B (Tempus ECG-Low EF) explicitly states 'has_baa: yes', offering clear transparency regarding Business Associate Agreements, whereas Tool A (cmAngiou00ae) requires contacting the vendor for BAA details.
Innovation
cmAngio®Both tools apply AI innovatively to diagnostic data. Tool A (cmAngiou00ae) stands out by transforming routine mammography into a dual-purpose exam for cardiovascular risk assessment, being the 'first and only FDA-cleared AI software' for detecting BAC on mammograms. This repurposing of existing imaging data for a new, critical health insight represents a particularly innovative approach.
Support & Docs
TieNeither the provided structured facts nor the web search results offer sufficient specific details regarding customer support channels, service level agreements, or the comprehensive nature and accessibility of documentation for either Tool A or Tool B. Therefore, a definitive winner cannot be determined.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | Tempus ECG-Low EF |
|---|---|---|
| Name | cmAngio® | Tempus ECG-Low EF |
| Company | CureMetrix | Tempus AI |
| Description | FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. | FDA-cleared AI software that analyzes 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction (LVEF ≤40%) in patients 40 years or older at risk of heart failure. It provides a binary output to aid clinicians in further evaluation. |
| Primary Function | AI-based detection of Breast Arterial Calcifications (BAC) on mammograms. | AI-powered algorithm for ECG analysis to detect signs of low Left Ventricular Ejection Fraction (LVEF ≤40%). |
| Target Patient Population | Women undergoing routine screening mammography. | Patients 40 years or older at risk of heart failure. |
| Input Data | Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams. | Resting, non-ambulatory 12-lead ECG recordings. |
| Output | Visualization of BAC location on a scorecard, BAC identification and reporting. | Binary output (Low LVEF Detected / Not Detected). |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and Tempus ECG-Low EF.
Frequently Asked Questions
More Comparisons
More matchups featuring cmAngio® or Tempus ECG-Low EF
Backers
Who funded each tool's parent company.